Company Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache.
Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis.
It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain.
It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
| Country | United States |
| Founded | 1876 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 47,000 |
| CEO | David Ricks |
Contact Details
Address: Lilly Corporate Center Indianapolis, Indiana 46285 United States | |
| Phone | 317 276 2000 |
| Website | lilly.com |
Stock Details
| Ticker Symbol | LLY |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000059478 |
| CUSIP Number | 532457108 |
| ISIN Number | US5324571083 |
| Employer ID | 35-0470950 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David A. Ricks | Chairman, Chief Executive Officer and President |
| Dr. Daniel M. Skovronsky M.D., Ph.D. | EVice President, Chief Scientific Officer and President of Lilly Research Laboratories and Lilly immunology |
| Anat Hakim J.D. | Executive Vice President, General Counsel and Secretary |
| Jacob S. Van Naarden | Executive Vice President and President of Loxo |
| Lucas E. Montarce | Executive Vice President and Chief Financial Officer |
| Donald A. Zakrowski | Senior Vice President of Finance and Chief Accounting Officer |
| Diogo Rau | Executive Vice President and Chief Information and Digital Officer |
| Eric Dozier | Executive Vice President of Human Resources and Diversity |
| Jeffrey N. Simmons | Senior Vice President and President of Elanco Animal Health |
| W. Darin Moody | SVice President of Global Active Pharmaceutical Ingredient, Dry Products Mfg and Continuous Improvement Division |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 19, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 19, 2025 | 10-K | Annual Report |
| Feb 13, 2025 | 144 | Filing |
| Feb 12, 2025 | 8-K | Current Report |
| Feb 11, 2025 | 424B2 | Prospectus |
| Feb 10, 2025 | FWP | Free Writing Prospectus |
| Feb 10, 2025 | 144 | Filing |
| Feb 10, 2025 | 424B2 | Prospectus |
| Feb 7, 2025 | SCHEDULE 13G/A | Filing |
| Feb 6, 2025 | 144 | Filing |